Turkeri, Levent
(Department of Urology, Faculty of Medicine, Marmara University)
Mangir, Naside (Department of Urology, Faculty of Medicine, Marmara University) Gunlusoy, Bulent (Izmir Teaching and Research Hospital) Yildirim, Asif (Urology Clinic, Goztepe Teaching and Research Hospital) Baltaci, Sumer (Department of Urology, Faculty of Medicine, Ankara University) Kaplan, Mustafa (Department of Urology, Faculty of Medicine, Trakya University) Bozlu, Murat (Department of Urology, Faculty of Medicine, Mersin University) Mungan, Aydin (Department of Urology, Faculty of Medicine, Karaelmas University) |
1 | Arianayagam M, Arianayagam R, Rashid P (2011). Lower urinary tract symptoms-current management in older men. Aust Fam Physician, 40, 758-67. |
2 | Budman LI, Kassouf W, Steinberg JR (2008). Biomarkers for detection and surveillance of bladder cancer. Can Urol Assoc J, 2, 212-21. |
3 | Chou R, Dana T (2010). Screening adults for bladder cancer: A review of the evidence for the u.S. Preventive services task force. Ann Intern Med, 153, 461-8. DOI |
4 | Davis R, Jones JS, Barocas DA, et al (2012). Diagnosis, evaluation and follow-up of asymptomatic microhematuria (amh) in adults: AUA Guideline. J Urol, 188, 2473-81. DOI |
5 | Elias K, Svatek RS, Gupta S, Ho R, Lotan Y (2010). High-risk patients with hematuria are not evaluated according to guideline recommendations. Cancer, 116, 2954-9. DOI |
6 | Grossfeld GD, Wolf JS, Litwan MS, et al (2001). Asymptomatic microscopic hematuria in adults: Summary of the aua best practice policy recommendations. Am Fam Physician, 63, 1145-54. |
7 | Jung H, Gleason JM, Loo RK, et al (2011). Association of hematuria on microscopic urinalysis and risk of urinary tract cancer. J Urol, 185, 1698-703. DOI |
8 | Khadra MH, Pickard RS, Charlton M, Powell PH, Neal DE (2000). A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice. J Urol, 163, 524-7. DOI ScienceOn |
9 | Lokeshwar VB, Habuchi T, Grossman HB, et al (2005). Bladder tumor markers beyond cytology: International consensus panel on bladder tumor markers. Urology, 66, 35-63. DOI ScienceOn |
10 | Lokeshwar VB, Soloway MS (2001). Current bladder tumor tests: Does their projected utility fulfill clinical necessity? J Urol, 165, 1067-77. DOI ScienceOn |
11 | Lotan Y, Elias K, Svatek RS, et al (2009). Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker. J Urol, 182, 52-7. DOI ScienceOn |
12 |
Ludecke G, Weidner, W. (2006). |
13 | Moonen PM, Kiemeney LA, Witjes JA (2005). Urinary NMP22 BladderChek test in the diagnosis of superficial bladder cancer. Eur Urol, 48, 951-6 DOI ScienceOn |
14 | Hee T, Shah S, Ann H, et al (2013). Stratifying patients with haematuria into high or low risk groups for bladder cancer: A novel clinical scoring system. Asian Pac J Cancer Prev, 14, 6327-30. 과학기술학회마을 DOI |
15 | Ng KL, Htun TH, Dublin N, Ong TA, Razack AH (2012). Assessment and clinical significance of haematuria in Malaysian patients - relevance to early cancer diagnosis. Asian Pac J Cancer Prev, 13, 2515-18. 과학기술학회마을 DOI |
16 | Turkeri L, Tinay I (2008). Advances in the understanding of the early detection of bladder cancer. Eur Urol Review, 3, 28-30. |
17 | Turkeri L, Turker P, Gunlusoy B, et al (2008). Multicenter evaluation of a questionnaire-based screening tool in urethelial carcinoma of the bladder. J Urol, 179, 321. |
![]() |